EGFR and non-small cell lung carcinoma: Despite the routine recommendations on testing of EGFR mutation for NSCLC across countries [3, 28], region and heath-system specific cost-effectiveness analysis on the use of testing-guided therapy is highly warranted to inform healthcare policy decision makers on selection of new NSCLC treatment strategies.